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Abstract
The etiology of human autoimmune diseases in general remains largely unknown, although the 
genetic and environmental interplay may be relevant. This applies to the autoimmune diseases of 
the skin such as the pemphigus phenotypes and others. In this group, there is an endemic form of 
pemphigus foliaceus [also known as Fogo Selvagem (FS)] where the pathogenic IgG4 
autoantibody response to the self-antigen, Desmoglein 1 (Dsg1) cross-react with the LJM11 sand 
fly salivary gland antigen. In this investigation we dissected the IgG4 autoantibody repertoires 
utilized by FS patients in response to endogenous self Dsg1 and exogenous LJM11 sand fly 
antigen. Based on analyses of the genetic clonal signatures of these antibodies, our results indicate 
that there is a significant overlap between these two responses as all identified IgG4 monoclonal 
antibodies cross-react to both Dsg1 and LJM11 antigens. Germline H and L chain V gene 
antibodies generated according to mutated cross-reactive monoclonal antibodies preserved their 
reactivity to both antigens. Our findings suggest that both Dsg1 autoantigen and LJM11 
environmental antigen could be the initial antigenic stimulants for the IgG4 autoimmune responses 
in FS. These results support our hypothesis that LJM11 antigen plays a substantial role in 
triggering the IgG4 autoantibody development in FS, and provide new insights on how non-
infectious environmental antigen(s) may drive the generation of autoantibodies in IgG4-related 
autoimmune diseases.
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Introduction
Fogo Selvagem (FS) is an endemic form of pemphigus foliaceus (PF) found in certain states 
of Brazil (1, 2). The hallmark of this disease is the presence of intraepidermal vesicles due to 
epidermal cell detachment (acantholysis) (3) induced by pathogenic IgG4 anti-desmoglein 1 
(Dsg 1) autoantibodies (autoAbs) (4–8). FS shows similar clinical, histological and 
immunological features to those observed in non-endemic PF (9, 10). Epidemiologic and 
immunogenetic studies suggest that both genetic and environmental factors contribute to the 
development of FS (1, 11, 12). Previous studies suggest that exposure to hematophagous 
insect bites in genetically predisposed individuals may be a risk factor for FS (12). To 
strengthen this hypothesis we have shown that IgG4 anti-Dsg1 autoAbs cross-react with 
LJM11 sand fly salivary gland antigen (13), which suggests that the development of IgG4 
Abs may be linked to immune responses to environmental antigens. Compared to 
investigations on the pathogenesis and genetic predisposition of autoimmune diseases, 
etiological studies regarding environmental triggers of these diseases are lacking due to low 
prevalence and the clinical heterogeneity of the diseases (14–19). Similarly, the random 
nature of autoimmune skin diseases in North America makes it difficult to assess their 
etiological commonality and further dissect their causes. In this regard the endemic nature of 
FS provides an invaluable model and rare opportunity to study the environmental factors 
within the FS endemic region and their contribution to the development of FS.
IgG4 Abs are known to be elevated in patients with FS (20–22), other bullous dermatoses 
(23), as well as autoimmune pancreatitis (24), Mikulicz's disease (primary Sjogren's 
syndrome) (25), and other diseases (26). Recently, the terms “IgG4-related disease” and 
‘IgG4-related skin disease” have been proposed (26–28). Among some autoimmune 
diseases, increased serum levels of total IgG4 are often observed and certain specific 
histopathological features, such as IgG4 plasma cell infiltration in effected tissues or organs, 
are present. (26–28). On the other hand, increased circulating anti-Dsg1 IgG4 autoAbs are 
characteristic of FS/PF as these anti-epidermal autoAbs are pathogenic and are detected 
bound to the surface of detached keratinocytes in lesional and perilesional epidermis of these 
patients (4). In FS/PF the lesional skin does not show IgG4 B cell or plasma cell infiltrates. 
In 1989 Rock et al demonstrated that the IgG4 response in FS is pathogenic (20). Later 
studies confirmed that the bulk of pathogenic anti-Dsg1 autoAbs in FS are predominantly 
IgG4 (21). IgG4 anti-Dsg 1 Abs from FS patients are pathogenic in mice (8, 29); similar to 
those in PF (30) using an IgG passive transfer mouse model. One study showed that 
progression from the preclinical to the clinical stage of the disease is associated with a 
dramatic rise in IgG4 anti-Dsg1 autoAbs (21) and that the level of anti-Dsg1 IgG4 Abs can 
be used as a predictor of FS (22). Our recent finding that IgG4 autoAbs in FS cross-react 
with an LJM11 sand fly antigen (13) suggests that the development of IgG4 autoAbs in 
patients may be linked to exposure to an environmental antigen. The studies of the 
association of environmental factors, such as infectious agents, with the development of 
autoimmune diseases have a long history (15, 17–19, 31–34). However, the studies of non-
infectious antigens and their association with the development of autoimmune diseases are 
scarce. Since sand flies are prevalent in FS endemic areas, it is possible that individuals 
living in these endemic regions, especially among those FS susceptible individuals, may 
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generate an immune response to antigens from sand fly saliva (i.e. LJM11). The LJM11 
antigen, a member of the “yellow family” of salivary proteins is one of the most 
immunogenic component among the sand fly saliva proteins and is also a marker for human 
exposure of sand fly bites (35). Given that anti-LJM11 Abs cross-react to autoantigen Dsg1 
(13, 36) strongly suggests the existence of a “cross-reactive” epitope(s) on both LJM11 and 
Dsg1. Since exposure to exogenous antigens may induce the autoimmune response 
to ”cross-reactive” autoantigens in autoimmune diseases (33, 34, 37–39), we hypothesize 
that the immune response directed against this “cross-reactive” epitope(s) subsequently 
initiates the generation of IgG4 autoAbs in FS susceptible individuals.
The aim of this investigation was to determine if the IgG4 autoAb responses to Dsg1 and 
LJM11 sand fly antigens overlap at the Ab V gene level on FS patients from endemic areas. 
Our study indicates that there is a striking overlap between these two IgG4 responses and 
LJM11 could be an inciting antigen for autoAb development, strongly suggesting that 
LJM11 sand fly antigen plays an important role in the etiology of FS.
Materials and Methods
Immortalized B cell samples from FS patients
Immortalized B cell samples from FS patients in this investigation have been described 
before (40) and kept at the University of North Carolina Dermatology Research 
Laboratories. These studies are approved by the institutional review boards from the 
University of North Carolina at Chapel Hill.
IgG4 Ab phage display library construction
To amplify the VH and VL genes for Ab phage display (APD) library construction, mRNA 
from the immortalized B cells of three FS patients (13) were isolated and their cDNA were 
synthesized. The L chain V genes were amplified as originally described (41). To obtain 
IgG4 only H chain genes, we used the 5’ primers described from the original method (41), 
while the 3’ primers for VH genes from the original method (41) were replaced by an IgG4 
specific primer based on an IgG4 Ab constant region specific sequence designed by 
Efremov et al (42). A 209 bp DNA segment from the heavy chain constant region (including 
36bp from the IgG4 hinge region) was amplified along with the H chain V genes transcripts. 
The resulting IgG4 scFv (single-chain fragment variable) comprises L and H chain V 
segments and partial constant region of IgG4 H chain (Supplemental Figure 1). The 
subsequent APD library construction was according to the original method described (41). 
To introduce FLAG-tag at the N-terminal of the resulting scFv for more convenient 
detection and purification, the original pComb3xSS vector was modified. The primer 
sequences used for PCR are: 
5’ATAGGCCAGGCCGGCCAGCACCATCACCATCACCATTAGGAGGGTGGTGGCT
CTG3’ (for removing HA at C-terminal) and 
5’ATAGGCCGCCTGGGCCAACTTGTCATCGTCATCCTTGTAATCCGCAGCTTGGG
CCACGGTAGCGAA3’ (for adding FLAG at N-Term). PCR cycle: 94°C-4 min for one 
cycle; 94°C-30 sec/55°C-30 sec/72°C-5 min for 30 cycles; 72°C-10 min for one cycle. This 
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PCR product was SfiI digested and cloned to modified pComb3xSS vector (with FLAG-tag 
at the N-terminal).
Isolation of anti-Dsg1, anti-LJM11, and cross-reactive mAbs
The constructed IgG4 APD libraries were panned as described (41) against either Dsg1 or 
LJM11 for three rounds, or the alternation of Dsg1 and LJM11 for total of four rounds 
(Supplemental Table I). These selected clones were amplified and their H and L chain 
sequenced. Selected clones were subjected to scFv protein expression and production. 
Produced scFv mAbs were purified by either Nickel column (Qiagen, CA) or anti-FLAG 
magnetic beads (Sigma, MO) according to manufacturers’ instruction for further testing. 
Human Dsg1 and sand fly LJM11 protein were purified as described (13, 35, 36, 40, 43).
ELISA and other mAbs
The specificity of those purified scFv mAbs were tested by ELISA as previous described 
(13, 36, 40, 44). Negative control scFv (TT1) was kindly provided by Drs. Don Siegel and 
Stephen Kacir from University of Pennsylvania and was subcloned in our modified 
pComb3xSS vector with an N-terminal FLAG-tag. Anti-FLAG-HRP (Sigma, MO) was used 
as secondary Ab for detection of all purified scFv mAbs.
Revertant scFv mAbs
The germline sequences of the H and L chain of two mAbs (4E4 and 2D11) isolated 
previously (40) were identified using The National Center for Biotechnology Information 
(IgBlast) (45). The H and L chain V genes of the germline formats of these two mAbs were 
synthesized (Genscript, NJ) and subcloned into our modified pComb3xSS vector. The 
revertant scFv mAbs (4E4-R and 2D11-R) and their mutated counterpart scFv mAbs (4E4 
and 2D11) were expressed and purified as described (41).
VH gene analysis
The identified scFv mAb H chain genes were analyzed using Ab gene database at The 
National Center for Biotechnology Information (IgBlast) (45). Vector NTI (Invitrogen, MA) 
is used for multiple alignments of the VH genes.
Statistics
The significant difference between the ratio of replacement and silent mutations (R/S) for 
CDRs and FWRs is assessed using Chi-square test.
Results
Construction of IgG4 Ab Phage Display Libraries from FS B cells
Since the main pathogenic autoAbs are of the IgG4 subclass in FS (20, 21), we sought to 
focus on the characterization of IgG4 Abs from FS patients. The APD library constructed 
using the method originally described by Barbas et al (41) includes the Ab repertoire from 
all 4 IgG subclasses in a constructed IgG phage display library and the original IgG subclass 
identity could not be determined from resulting scFv Abs from the library. However, 
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because of the predominant presence of IgG4 Abs in autoimmune skin diseases (4–8) and 
other IgG4-related diseases (26), the identification and isolation of IgG4 mAbs from these 
patients became increasingly necessary to understand the mechanism of IgG4 Ab 
development in these patients. Thus, we have modified the method for our particular 
purpose to obtain only IgG4 mAbs (Supplemental Figure 1). The advantages of the resulting 
mAbs are that: (a) the scFv Abs in these libraries derived from FS B cells comprise IgG4 
Abs only, and (b) the scFv contain partial constant and hinge regions of IgG4 immediately 
following VH domain, and their IgG4 subclass identity can be further confirmed. Employing 
this strategy, we have constructed 3 IgG4 phage display libraries using mRNA isolated from 
3 FS patients’ EBV immortalized B cells.
Isolation of anti-Dsg1 and anti-LJM11 IgG4 mAbs by panning against Dsg1 and LJM11
We have shown that FS patients have significantly higher IgG4 anti-Dsg1 and LJM11 Abs 
compared to normal controls (HC) from both FS (Limao Verde in Brazil, LV) and non-FS 
(US) endemic region (36), suggesting that there are IgG4 immune responses against both the 
autoantigen and environmental antigen. Additionally, that two anti-Dsg1 IgG4 mAbs 
isolated from FS patients previously using hybridoma method cross-react to both Dsg1 and 
LJM11 (13) suggests the presence of cross-reactive epitope(s). Thus, it is possible that IgG4 
Abs are present in FS patients reacting to both Dsg1 and LJM11.
To determine whether there is an overlap between these anti-Dsg1 and anti-LJM11 IgG4 
responses, we identified the anti-Dsg1 and anti-LJM11 IgG4 Abs from the IgG4 APD 
libraries constructed from B cells of 3 FS patients to study the IgG4 Ab repertoires by 
panning against either Dsg1 and/or LJM11 (Supplemental Table I) (41). Colonies were 
randomly selected from Dsg1 and LJM11 panning of these three IgG4 APD libraries. Their 
plasmids were purified and subject to sequencing using Ompseq and HRML-F primers as 
described (41). The Ab H and L chain gene sequencing results of selected Ab clones from 
IgG4 APD libraries were analyzed using Ab gene database at The National Center for 
Biotechnology Information (IgBlast) (45), and their four framework regions (FWRs) and 
three complementary determining regions (CDRs) determined. Totals of 39 (GCDS), 58 
(FGS), 39 (JLDO) clones from Dsg1 and LJM11 panning, were successfully sequenced and 
their VH and VL gene usages were determined. The additional H chain constant region 
sequences of these mAbs were also analyzed and confirmed to be of IgG4 subclass, 
indicating that only IgG4 mAbs were identified from our constructed IgG4 APD libraries.
Same parental B cell origins by IgG4 mAb clones isolated from panning of IgG4 APD 
libraries against either Dsg1 autoantigen or LJM11 environmental antigen
The H chain V regions of mAbs from pemphigus are known to contribute most of the Dsg 
binding. For example, Di Zenzo et al (46) demonstrated that H chain V gene somatic 
mutations are required for mAbs to maintain its binding to Dsg3 while L chain V gene 
mutations are not required for their binding to Dsg3. Studies from Stanley group indicated 
that the H chain of an anti-Dsg mAb could pair with L chains encoded by different VL genes 
without losing its Dsg specificity (47–50). Consistent with all these previous findings, we 
also found that most of independent mAbs identified from either Dsg1 or LJM11 panning of 
FS IgG4 APD libraries have different L chains paired with the same H chains (data not 
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shown). Therefore, all our genetic analyses of these mAbs in this investigation are centered 
on the H chain V gene segments. Among all three CDRs, the CDR3 region is the most 
diverse part of the antibody V regions and a unique CDR3 sequence represents the genetic 
clonal signature for a group of Abs derived from the same parental B cell. Based on their H 
chain V gene usage and the clonal signature of clonally related Abs (51), these clones can be 
grouped to 4, 6, and 4 independent clones from 3 FS patients, respectively (Table I). It 
should be noted that the VH genes of two IgG4 mAbs (GCDS-2D11 and FGS-4E4) that 
were isolated using hybridoma method from our previous study (40) are also identified from 
these clones isolated in our current study. The H chain of GCDS-2D11 is encoded by 
IGHV2-5 while that of FGS-4E4 is encoded by IGHV3-48. Both clusters of mAbs encoded 
by these two VH genes and their respective CDR3s are identified from their corresponding 
IgG4 APD libraries (both VH genes are in bold in Table I). It indicates that antigen-specific 
mAbs can be identified using both hybridoma and APD libraries, further validating our 
newly developed method for construction and panning of IgG4 APD libraries to identify 
only IgG4 mAbs.
We next used two methods to further determine whether these mAbs are cross-reactive to 
Dsg1 and LJM11. These three IgG4 APD libraries were panned against the alternation of 
Dsg1 and LJM11 for total four rounds (panned against Dsg1 for 1st and 3rd rounds, and 
panned against LJM11 for 2nd and 4th rounds) (Supplemental Table I) to identify cross-
reactive mAbs. Those identified clones were sequenced and compared to those clones 
identified from Dsg1 or LJM11 individual panning. Most mAbs found from Dsg1 and 
LJM11 only panning are also found from the Dsg1/LJM11 alternate panning, and thus 
determined to be cross-reactive. Some representative scFv were produced and purified as 
described (41) and tested by both anti-Dsg1 and LJM11 ELISA (40, 44). All ELISA tested 
mAbs are cross-reactive (Table I and data not shown). Three independent clones isolated 
from either Dsg1 or LJM11 individual panning (one from GCDS and two from FGS, 
highlighted in gray in Table I) also cross-react to both Dsg1 and LJM11. Thus all the clones 
identified from our panning were cross-reactive based on one or the combination of two 
methods, and the results are summarized in Table I. Accordingly, despite differences in their 
mutations in complementary determining regions (CDRs) and framework regions (FWRs) of 
those mAbs in each individual clonal lineage (see below and Figure 1) their specificity to 
both Dsg1 and LJM11 is conserved.
Clonal selection and expansion among Anti-Dsg1/LJM11 mAbs
Studies on some autoimmune diseases suggest that the autoimmune response in these 
diseases involves clonal selection and expansion events and is often oligoclonal (53). In the 
present investigation, we isolated a total of 14 independent clones from 136 Dsg/LJM11 
specific clones. It appears that autoimmune response within each individual patient is 
oligoclonal since only a limited number of independent clones were isolated. Some of the 
mAbs used the same VH genes by different FS patients. For example, IGHV1-18, 
IGHV1-69, and IGHV4-34 are shared by patients FGS and JLDO, with different CDR3 
sequences between each linage of mAbs from these two patients (Table I). Some of the 
mAbs from two patients share the same VH genes, suggesting there is a level of constrained 
VH gene usage in FS, consistent with other studies on the Ab repertoire in autoimmune 
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diseases (53). The analyses of VH genes of these mAbs identified from panning of IgG4 
APD libraries also demonstrate that the clonal expansion is apparent in all three patients. 
Phylogenetic trees in Figure 1 suggest that evolutionarily these clones originated from the 
same parental B cells. For example, on the top left panel, all these Abs from patient GCDS 
are all encoded by IGHV5-51 VH gene and have the same CDR3 sequence. The VH genes 
of these Abs originated from the germline gene IGHV5-51 and underwent somatic mutation 
and clonal expansion during their maturations (see below). It is apparent that there is no 
divergent development among these mAbs identified from panning against either Dsg1 
(clones initiated with D in Figure 1) or LJM11 (clones initiated with L in Figure 1). Most of 
the Dsg1 and LJM11 clones can be found on the same branches; further suggesting that 
Dsg1 and LJM11 have shared epitope(s) and both may serve as the selecting antigen for 
driving the development of these Abs.
It is interesting that the H-CDR3 of two independent clones from one patient (GCDS) have 
D/ExxxW consensus sequences (in bold in Table I), which is the same as shared amino acid 
sequences in pathogenic pemphigus mAbs (50). Two H-CDR3 of independent clones from 
another patient also have YYYY aromatic amino acid clusters (in bold in Table I), similar to 
a pathogenic mAb from another study (46).
Extensive mutations among anti-Dsg1/LJM11 IgG4 Abs in FS patients
As it has been shown, those mutations are not the results of PCR errors through 
amplification of H and L chain V genes during APD library constructions (47). To further 
determine whether there are any characteristic mutations of anti-Dsg1 and anti-LJM11 IgG4 
Abs in FS during their evolution, the somatic mutations of five lineages of mAb clones were 
identified using IgBlast and aligned (Figure 2). All mAbs isolated from the libraries are 
extensively mutated, both in their CDRs and FWRs (Figure 2). Similar to those phylogenic 
analyses shown in Figure 1, the different mutations among different clones in the same 
lineages of mAbs (using the same VH genes) demonstrate clear step-wise mutation during 
their evolutions, consistent with continuous antigenic stimulation. One striking consistency 
is that despite extensive different FWR mutations among those different clones of the same 
clonal lineage, almost all the mutations at CDR regions are preserved. For example, clones 
from IGHV3-23 lineage of JLDO shown in Figure 2 (bottom panel highlighted in red), all 
mutations at CDR1 and CDR2 are identical (C63T, G89C, and G92A in CDR1, and 
G15157A, G158A, G161A, T165C, and A172G in CDR2). In contrast, there is at least one 
mutation difference at FWRs for these listed clones using the same VH gene (IGHV3-23). In 
addition, as shown in Figure 3 using GCDS-L3 as an example, except one mutation at CDR2 
(T-C mutation), all other mutations at CDR1 and CDR2 are replacement mutations which 
result in the change of amino acids compared to the germline VH (IGHV3-9). Those highly 
preserved replacement mutations at CDRs suggest that they were specifically favored during 
affinity maturation of these mAbs during their evolution. The average ratios of replacement 
mutations versus silent mutations (R/S) in CDRs are 2.47, 2.27, and 7.92, respectively, for 
the three FS patients, which is significantly higher than that in FWR (1.08, 1.17, and 1.26) 
(χ2 test, p<0.001) (Table II). The CDR R/S ratios of 10 clones (in bold in Table II), out of 
total of 14 independent clones are higher than 2.9, which also indicates antigen selection 
(54). Highly diverse nucleotide mutations on the same VH clone clusters suggests that these 
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mAbs underwent multiple rounds of clonal expansion, consistent with our hypothesis that 
chronic antigenic stimulation (by either self or environmental antigen, or both) is a feature 
for FS Ab development.
Shared mutations have been found previously in CDRs of the same VH genes encoding anti-
Dsg1 mAbs among FS patients and an individual before the onset of FS (40). To determine 
whether particular shared mutations are necessary for the development of the Dsg1/LJM11 
specificity, the three shared VH genes (IGHV1-18, IGHV1-69, and IGHV4-34) from two FS 
patients (FGS and JLDO) were aligned to identify shared mutation among them. However, 
no shared mutation is present among all these VH gene-sharing mAbs between those from 
two patients (Figure 4). Furthermore, the CDR3 sequences of these VH gene-sharing mAbs 
from two patients are also different as shown in Table I. In general, H chain CDR3 is 
important for Ab specificity (55, 56). Though our result suggests that the Dsg1/LJM11 
specificity of cross-reactive Abs from FS may be governed by the combination of all three 
CDR sequences rather than by a single CDR such as CDR3. This suggests that the Ab 
response in different individuals is flexible and may have multiple routes to achieve the 
same specificity during the positive selection of their respective Ab evolution. The extensive 
mutations in FWRs among those FS autoAbs (Table II) suggest that those mutations may 
also aid in improving the affinity of these autoAbs to their target antigens in FS, as found 
previously in broadly neutralizing Abs to HIV-1 (57).
Germline VH and VL encoded revertant mAbs from FS recognize both Dsg1 and LJM11
The wide presence of Dsg1 and LJM11 cross-reactive Abs in FS suggests that either Dsg1 or 
LJM11, or both may participate in driving the development of these Abs. However, it does 
not reveal whether Dsg1 or LJM11 could be the initial target for the naïve B cells in FS. It is 
also possible that some other antigens (either environmental or self), but not Dsg1 or LJM11 
is the initial target that activates the naïve B cells which are the precursors for the eventual 
plasma cells that secrete these autoreactive Abs in FS. Therefore, it would be interesting to 
determine if naïve B cells expressing germline V genes can bind Dsg1 and LJM11.
The mutations in the VH and VL genes of two cross-reactive mAbs, namely FGS-4E4 and 
GCDS-2D11 (their VH are in bold in Table I) which were found using both hybridoma 
method (13, 40) and APD method, were identified using IgBlast (45) and reverted back to 
the germline configurations (Figure 5A). The DNA of the germline VH and VL genes of 
these two revertant mAbs were synthesized, subcloned into the original modified 
pComb3xSS vector (Methods), produced and purified as scFv (4E4-R and 2D11-R). The 
reactivity of these two revertant mAbs to Dsg1 and LJM11 was tested by ELISA and 
compared to that of their mutated counterpart scFv. As shown in Figure 5B, these two 
revertant scFv react to both Dsg1 and LJM11. This suggests that either Dgs1 or LJM11 (or 
both) may be the initial target(s) of autoimmune responses in FS, further implicating the 
environmental contribution to the development of FS.
Discussion
Our previous studies regarding the presence of cross-reactive mAbs in FS patients (13) 
suggest that there might be an overlap between the immune responses towards these two 
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antigens. In this investigation we seek to disclose the presence of an overlap between IgG4 
responses against either Dsg1 or LJM11 in FS. Based on our hypothesis, the cross-reactive 
epitope(s) on Dsg1 and LJM11 would drive the development of cross-reactive Abs in FS. 
Due to the polyclonal nature of the Abs in patients’ sera, the cross-reactivity of those IgG4 
Abs can only be determined using monoclonal IgG4 Abs. The construction of IgG4 specific 
APD libraries and the subsequent panning of these libraries against either autoantigen or 
environmental antigen, i.e. LJM11 sand fly antigen make it possible to identify these 
antigen-specific IgG4 Abs. Compare to the hybridoma method utilized in our previous 
investigation on FS Ab development (40), our newly developed IgG4 APD method modified 
from original APD method (41) has a distinct advantage over the hybridoma method. For 
example, only two IgG4 mAbs were isolated using hybridoma method even several 
thousands of hybridoma clones were screened from 8 FS patient B cell samples ((40) and 
(unpublished data)). However, 14 IgG4 independent mAb clones are isolated from three FS 
patients using this IgG4 APD method. It indicates that IgG4 APD method has broader 
coverage of the Ab repertoire than hybridoma method does. Moreover, this newly developed 
IgG4 APD method may have a wider application to the study of IgG4 Ab repertoires of 
other IgG4-related diseases in the future.
The presence of cross-reactive mAbs in FS (13) also suggests the presence of cross-reactive 
epitope(s) between autoantigen Dsg1 and environmental antigen LJM11. Notably, these two 
molecules are evolutionary distant and share little primary sequence homology. The cross-
reactive mAbs from FS patients bind both molecules via conformational epitope (13) which 
does not rely on the similarity of the linear sequences of them. This explains the possible 
presence of a “cross-reactive” epitope on both molecules and also suggests that there are 
other epitopes on both molecules which are not cross-reactive, such as those epitopes that 
consist of continuous amino acids (linear epitopes). Thus, besides these Abs derived against 
the cross-reactive epitope(s) on both molecules, it should be expected that there are Abs 
from FS patients that are either Dsg1- or LJM11-specific which do not cross-react to the 
other. It is quite surprising that all mAbs identified from our investigation are cross-reactive, 
regardless of whether they are obtained from panning against Dsg1 or LJM11. Even though 
it might be unlikely, we cannot rule out that these two molecules share more than one 
conformational epitopes. Hence it is possible that these mAbs bind different “cross-reactive” 
epitopes shared by these two molecules. Still, there might be other explanations. For 
example, the current screening method for mAb clones identified by panning of APD 
libraries only allows us to examine a limited number of clones. Thus, it is possible that only 
the most abundant clones were captured while those rare clones, such as Dsg1- or LJM11-
specific, escaped the detection. Nevertheless, the detection of identical and clonally related 
clones indicates that the most abundant IgG4 mAbs in these FS patients have been disclosed 
and the presence of these cross-reactive IgG4 demonstrates the possible contribution of the 
environmental antigen in FS development. The rapid development of next generation 
sequencing method for high throughput Ab sequence analysis will make it possible to 
identify those rare clones if the need arises in the future (58).
Another implication of our finding is that the cross-reactive epitope(s) might be the most 
immunogenic (or most dominant) that induces the strongest immune response against this 
epitope(s), as the conservation of the CDR mutations among most VH sharing mAbs 
Qian et al. Page 9
J Immunol. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
identified from the same patient is remarkably stable. Thus, most IgG4 Abs from FS patients 
might be developed against this epitope. LJM11 is known to be the most immunogenic 
component in sand fly saliva (35) and it might be due to this cross-reactive epitope. In this 
regard, the cross-reactive epitope on Dsg1 must be a predominant epitope for the 
development of anti-Dsg1 Abs in FS. The presence of a predominant epitope is corroborated 
by other investigations on pemphigus. For instance, it has been shown that one predominant 
pathogenic epitope on Dsg1 may be targeted by most PF patients, as the binding of an anti-
Dsg1 pathogenic mAb can be inhibited by sera from these patients (48). Similarly, there is 
also an immunodominant epitope on Dsg3 in mucocutaneous PV (46). Not only is the 
binding of a pathogenic mAb from a PV patient to Dsg3 inhibited by these tested PV sera, 
this pathogenic mAb also inhibits PV polyclonal Abs from binding to Dsg3 (46). Therefore, 
it is possible that all these mAbs isolated from this study target one conformational epitope 
shared by Dsg1 and LJM11, or epitopes in the vicinity of or overlapping this epitope.
The isolated cross-reactive mAbs could be either pathogenic or not pathogenic. If these 
IgG4 autoantibodies are pathogenic, it would indicate that an environmental antigen may be 
directly involved in driving the pathogenic IgG4 autoantibody response in FS. If they are not 
pathogenic, it would suggest that these IgG4 autoantibodies may play a role in activating an 
extended autoantibody response, via mechanisms such as epitope spreading in FS, and this 
subsequent autoantibody response leads to the development of pathogenic autoantibodies in 
FS as demonstrated before (59). In either case, the inciting antigen(s) (Dsg1 and/or LJM11) 
would be directly and/or indirectly involve in the development of pathogenic IgG4 
autoantibodies in FS.
The current study also demonstrates that a non-infectious environmental antigen may 
contribute to the initiation of an autoimmune disease. It is possible, as shown in a previous 
study (36), that these FS-genetically susceptible individuals mount an IgE response to sand 
fly antigen exposure. They then develop IgG4 Abs in response to the repeated (chronic) 
exposure to sand fly bites, because of the well-known transition from IgE to IgG4 during 
chronic antigenic stimulation or allergen-specific immunotherapy in allergy (60–63). These 
IgG4 Abs turn out to be cross-reactive to Dsg1 autoantigen. Those anti-Dsg1 IgG4 Abs 
themselves or their triggered subsequent development of additional anti-Dsg1 IgG4 Abs 
result in the development of FS in those genetically susceptible individuals.
It is noteworthy that reverting mutated IgG4 autoAbs from FS back to their germline VH 
and VL genes do not abolish their reactivity to both Dsg1 and LJM11. Numerous studies 
using revertant Abs to study human autoimmune diseases, such as pemphigus vulgaris and 
Systemic Lupus Erythematosus indicate that the revertant Abs lose their reactivity (46, 64) 
or have reduced reactivity (65) to their corresponding autoantigens once their H and L chain 
V regions reverted back to their germline formats. AutoAb development from non-
autoreactive B cells has been proposed (64, 65). Due to the lack of candidate antigenic 
stimulants for triggering the development of these autoAbs in human autoimmune diseases, 
the initial targets (except these autoantigens of their corresponding autoimmune diseases) for 
these naïve B cells could not be further identified using revertant mAb method. In this study 
we provide evidence that environmental antigens, such as LJM11 from sand fly, could be an 
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antigenic stimulant that activates the naïve B cells in those individuals who are genetically 
predisposed to FS disease, and the subsequent development of IgG4 autoreactive Abs.
In summary, the extensive overlap of the IgG4 responses towards both Dsg1 autoantigen 
and LJM11 environmental antigen in this study is consistent with our hypothesis and thus 
establishes the possible link between the exposure to a non-infectious environmental antigen 
and the development of IgG4 autoAbs in FS. Moreover, that revertant mAbs also cross-react 
to both autoantigen (Dsg1) and environmental antigen (LJM11), provides further evidence 
that LJM11 could be the environmental antigen that triggers the activation of naïve B cells. 
All this evidence strongly suggests that LJM11 component from sand fly saliva as an 
environmental antigen may trigger the development of IgG4 autoAbs in FS susceptible 
individuals in FS endemic regions. Our findings regarding the role of IgG4 response to an 
exogenous antigen in FS may be expanded to the understanding of the etiology of other 
IgG4-related autoimmune diseases.
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Figure 1. 
Phylogenetic tree of clonally related IgG4 antibodies isolated from panning of IgG4 ADP 
libraries. Clone names start with D indicate these clones were identified from Dsg1 panning 
while those start with L indicate they were identified from LJM11 panning.
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Figure 2. 
Alignments of clonally related IgG4 Abs identified from IgG4 ADP libraries. CDR1, CDR2, 
and partial CDR3 sequences are boxed in red. Mutated nucleotides are highlighted in red. 
One representative clone is selected for those clones that have the identical VH gene 
sequences.
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Figure 3. 
Cross-reactive IgG4 monoclonal antibody genes are extensive mutated, especially in CDRs 
(red boxes) compared to FWRs (blue boxes). The H chain gene of a representative clone is 
aligned with its germline gene. Amino acids from germline sequence changed as a results of 
replacement mutations are shown in purple.
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Figure 4. 
Alignments of IgG4 Ab clusters that use the same VH genes identified from two different 
patients. CDR1, CDR2, and partial CDR3 sequences are boxed in red. Clones from different 
patients, as well as the germline genes (bottom of each alignment panel) are separated by 
black lines. All nucleotide mutations are in red.
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Figure 5. 
Revertant mAbs derived from two cross-reactive anti-Dsg1 mAbs from FS also recognize 
both Dsg1 and LJM11. (A) H and L chain amino acid sequences of 4E4 (upper panel) and 
2D11 (lower panel) and their corresponding revertant counterparts (encoded by germline 
VH and VL genes). Only mutated amino acids are shown for the VH and VL chains of 4E4 
and 2D11. The amino acid sequences of CDR1, 2, and 3 of VH and VL are boxed. (B) 
Similar to mutated anti-Dsg1 IgG4 scFv mAbs, their revertant scFv mAbs also react to both 
Dsg1 (left panel) and LJM11 (right panel). The negative control scFv (TT1) does not react 
with either Dsg1 or LJM11. The reactivity of each scFv Abs to either Dsg1 (left panel) or 
LJM11 (right panel) is measured by relative light units (RLU) as previously described (36). 
The results shown are representative of three independent experiments with triplicates in 
each experimental group.
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Table II
Replacement(R) vs silent(S) mutation in CDRs and FWRs of VH genes of the IgG4 scFv from FS patients
Patient VH Total clones CDR (R/S1) FWR (R/S)
GCDS
IGHV2-5*021 4 12/4 8/10
IGHV3-9*01 18 108/18 112/183
IGHV3-53*04 2 12/6 36/16
IGHV5-51*03 15 46/44 144/68
Total 39 178/72 300/277
FGS
IGHV1-18*01 4 24/7 42/24
IGHV1-69*09 2 6/0 17/7
IGHV3-48*04 18 119/76 108/36
IGHV4-34*01 15 33/0 34/45
IGHV4-59*08 6 24/1 59/34
IGHV7-4-1*02 13 39/24 49/119
Total 58 245/108 309/265
JLDO
IGHV1-18*01 6 12/0 18/20
IGHV1-69*09 7 28/6 34/5
IGHV3-23*01 18 126/18 141/130
IGHV4-34*01 8 32/1 17/12
Total 39 198/25 210/167
1
Replacement/Silent mutations.
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